Similar outcomes have been documented in treatment with IV tPA with BP variability.
Short-term memory and levels of fatigue improved, but no benefit for depression was observed.
Those treated with DBS had a 50% lower risk of worsening motor symptoms compared to those on drug therapy alone.
Risk appeared to be correlated with RLS disease duration.
As many as 50% of neurotoxic chemotherapy patients experience CPN.
Those with the lowest B12 levels performed worse on cognitive and motor outcomes.
The drug helped to significantly improve social functioning, medication effects, and seizure worry in patients.
Cerebral microbleeds are a marker of vascular burden and should be aggressively pursued with treatment and preventive care.
The disorders react similarly to basal ganglia deep brain stimulation.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies